Lital Avni-Singer1, Carlos R Oliveira2, Ashlynn Torres3, Eugene D Shapiro2, Linda M Niccolai3, Sangini S Sheth4. 1. Department of Obstetrics, Gynecology, & Reproductive Sciences, School of Medicine, Yale University, New Haven, Connecticut. 2. Department of Pediatrics, School of Medicine, Yale University, New Haven, Connecticut. 3. Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut. 4. Department of Obstetrics, Gynecology, & Reproductive Sciences, School of Medicine, Yale University, New Haven, Connecticut. Electronic address: sangini.sheth@yale.edu.
Abstract
INTRODUCTION: Rates of immunization with human papillomavirus (HPV) vaccine among adolescent and young adult females remain suboptimal. There is a continued need to focus on catch-up immunization. Some hospitals in the United States have implemented inpatient postpartum HPV immunization programs (IPP-HPV) as part of a strategy to improve rates of catch-up immunization. Patients' perspectives are critical to facilitating broad adoption of IPP-HPV. The objectives of this study were to understand the experiences and perspectives of postpartum women recommended to receive HPV vaccine before hospital discharge and to identify facilitators of and barriers to program implementation. METHODS: We conducted in-depth semistructured interviews with postpartum women eligible for IPP-HPV. We used purposive sampling to ensure representation across race, ethnicity, and language. Interviews were analyzed using an iterative thematic approach. RESULTS: The median age of participants (n = 24) was 22 years (range, 15-26 years), and six had declined the inpatient dose of HPV vaccine. Overall, women viewed IPP-HPV favorably. Facilitators of program implementation included viewing HPV vaccine as prevention, normalization of the vaccine, convenience of IPP-HPV, and the experience of a patient-centered approach. Barriers included the peripartum environment and associated stress, vaccine hesitancy, and a lack of both awareness of and knowledge about HPV vaccine. CONCLUSIONS: IPP-HPV immunization is a strategy well-received by women for improving rates of catch-up immunization. The implementation of such programs may be optimized by increasing awareness that the vaccine is available and recommended for postpartum women, and by using a patient-centered approach that is sensitive to the needs of postpartum patients.
INTRODUCTION: Rates of immunization with human papillomavirus (HPV) vaccine among adolescent and young adult females remain suboptimal. There is a continued need to focus on catch-up immunization. Some hospitals in the United States have implemented inpatient postpartum HPV immunization programs (IPP-HPV) as part of a strategy to improve rates of catch-up immunization. Patients' perspectives are critical to facilitating broad adoption of IPP-HPV. The objectives of this study were to understand the experiences and perspectives of postpartum women recommended to receive HPV vaccine before hospital discharge and to identify facilitators of and barriers to program implementation. METHODS: We conducted in-depth semistructured interviews with postpartum women eligible for IPP-HPV. We used purposive sampling to ensure representation across race, ethnicity, and language. Interviews were analyzed using an iterative thematic approach. RESULTS: The median age of participants (n = 24) was 22 years (range, 15-26 years), and six had declined the inpatient dose of HPV vaccine. Overall, women viewed IPP-HPV favorably. Facilitators of program implementation included viewing HPV vaccine as prevention, normalization of the vaccine, convenience of IPP-HPV, and the experience of a patient-centered approach. Barriers included the peripartum environment and associated stress, vaccine hesitancy, and a lack of both awareness of and knowledge about HPV vaccine. CONCLUSIONS: IPP-HPV immunization is a strategy well-received by women for improving rates of catch-up immunization. The implementation of such programs may be optimized by increasing awareness that the vaccine is available and recommended for postpartum women, and by using a patient-centered approach that is sensitive to the needs of postpartum patients.
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: S Rachel Skinner; Anne Szarewski; Barbara Romanowski; Suzanne M Garland; Eduardo Lazcano-Ponce; Jorge Salmerón; M Rowena Del Rosario-Raymundo; René H M Verheijen; Swee Chong Quek; Daniel P da Silva; Henry Kitchener; Kah Leng Fong; Céline Bouchard; Deborah M Money; Arunachalam Ilancheran; Margaret E Cruickshank; Myron J Levin; Archana Chatterjee; Jack T Stapleton; Mark Martens; Wim Quint; Marie-Pierre David; Dorothée Meric; Karin Hardt; Dominique Descamps; Brecht Geeraerts; Frank Struyf; Gary Dubin Journal: Lancet Date: 2014-09-01 Impact factor: 79.321
Authors: Jason D Wright; Shravya Govindappagari; Neha Pawar; Kirsten Cleary; William M Burke; Patricia C Devine; Yu-Shiang Lu; Wei-Yann Tsai; Sharyn N Lewin; Thomas J Herzog Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Melissa B Gilkey; Mo Zhou; Annie-Laurie McRee; Melanie L Kornides; John F P Bridges Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-06-14 Impact factor: 4.254
Authors: Tanja Y Walker; Laurie D Elam-Evans; David Yankey; Lauri E Markowitz; Charnetta L Williams; Sarah A Mbaeyi; Benjamin Fredua; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2018-08-24 Impact factor: 17.586
Authors: Tanja Y Walker; Laurie D Elam-Evans; David Yankey; Lauri E Markowitz; Charnetta L Williams; Benjamin Fredua; James A Singleton; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2019-08-23 Impact factor: 17.586